Related Experiment Video

Updated: May 27, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs

Neelesh Sharma1, Alex A Adjei

  • 1Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.

Therapeutic Advances in Medical Oncology
|December 1, 2011
PubMed

Insights

Dysregulated c-MET signaling drives cancer progression and resistance. New c-MET pathway inhibitors show promising clinical activity and an acceptable safety profile in ongoing trials.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The c-MET (mesenchymal-epithelial transition factor) pathway is frequently dysregulated in human cancers.
  • Aberrant c-MET signaling promotes tumor growth, invasion, dissemination, and contributes to drug resistance and poor clinical outcomes.

Purpose of the Study:

  • To review the pharmacological profiles of drugs targeting the c-MET pathway.
  • To discuss data from ongoing clinical trials evaluating these c-MET inhibitors across various cancer types.

Main Methods:

  • Review of pharmacological data for c-MET inhibitors.
  • Analysis of preliminary clinical trial results (Phase I, II, and III) for c-MET targeted therapies.

Main Results:

  • A robust pipeline of c-MET inhibitors targeting various activation mechanisms is under clinical investigation.
  • Preliminary data indicate promising clinical activity and an acceptable toxicity profile for these agents.

Conclusions:

  • Targeted inhibition of the c-MET pathway represents a promising therapeutic strategy in oncology.
  • Ongoing clinical trials are essential for validating the efficacy and safety of c-MET inhibitors in diverse cancer indications.
Keywords:
MetMAbc-METcabozantinibforetinibtivantinib

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications14:14

Adaptation of Semiautomated Circulating Tumor Cell (CTC) Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...